OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Thrombosis and Thrombolysis is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Characteristics and comparisons of acute stroke in “recovered" to “active COVID-19 and “pre-pandemic” in Qatar database	54
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection	40
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery	36
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team	32
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry	29
Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians	27
Management of bone marrow biopsy related bleeding risks: a retrospective observational study	26
Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate	25
Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors	23
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison	21
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series	21
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding	21
Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy	19
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes	19
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients	17
Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies	16
Thrombosis in VEXAS syndrome	14
Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized tri	14
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum	14
Forensic autopsy-confirmed thrombosis-related deaths: the danger in the bones	13
Popliteal cysts are not a risk factor for lower extremity deep vein thrombosis	13
Metformin therapy in COVID-19: inhibition of NETosis	13
Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell’s viper venom time and silica clotting time increases thrombotic risk prediction	12
The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis	12
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study	11

Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study	11
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature	11
A comprehensive review of vascular complications in COVID-19	10
Time to consider neuroinflammation as a booster effect of cerebral venous sinus thrombosis in vaccine-induced immune thrombotic thrombocytopenia?	10
Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia	10
Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients	10